DOI QR코드

DOI QR Code

Association Between Three eNOS Polymorphisms and Cancer Risk: a Meta-analysis

  • Wu, Xun (Department of Anatomy, School of Basic Medicine Science, Southern Medical University) ;
  • Wang, Zhi-Feng (Department of Anatomy, School of Basic Medicine Science, Southern Medical University) ;
  • Xu, Yin (Department of Urology, The First Affiliated Hospital of JINAN University) ;
  • Ren, Rui (Department of Andrology, Zhongshan City People's Hospital) ;
  • Heng, Bao-Li (Department of Urology, The First Affiliated Hospital of JINAN University) ;
  • Su, Ze-Xuan (Department of Anatomy, School of Basic Medicine Science, Southern Medical University)
  • Published : 2014.07.15

Abstract

Polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may influence the risk of cancer, but the results are still debatable. Therefore, we performed a systematic review to provide a more complete picture and conducted a meta-analysis to derive a precise estimation. We searched PubMed, EMBASE, EBSCO, Google Scholar and China National Knowledge Infrastructure (CNKI) databases until April 2014 to identify eligible studies. Thirty-one studies with cancer patients and controls were included in the meta-analysis. Overall, the polled analysis revealed that the T-786C polymorphism was significantly associated with increased cancer risk under multiple genetic models (C vs T: OR=1.135, 95%CI=1.048-1.228; CC vs TT: OR=1.278, 95%CI=1.045-1.562; TC vsTT: OR=1.136, 95%CI=1.023-1.261; CC+TC vs TT: OR=1.159, 95%CI=1.047-1.281; CC vs TC+TT: OR=1.204, 95%CI= 1.003-1.447). G894T was associated with significant risk for females (TT vs GG: OR=1.414, 95%CI=1.056-1.892; TT vs GT+GG: OR=1.356, 95%CI=1.108-1.661) and for breast cancer (T vs G: OR=1.097, 95%CI=1.001-1.203; TT vs GG: OR=1.346, 95%CI=1.012-1.789; TT vs GT+GG: OR=1.269, 95%CI=1.028-1.566). Increased susceptibility was revealed for prostate cancer with 4a/b (ba vs bb: OR=1.338, 95%CI=1.013-1.768; aa+ba vs bb: OR=1.474, 95%CI=1.002-2.170). This meta-analysis indicated that the eNOS T-786C polymorphism is associated with elevated cancer risk; the G894T polymorphism contributes to susceptibility to breast cancer and cancer generally in females; and the 4a/b polymorphism may be associated with prostate cancer risk.

Keywords

References

  1. Amasyali AS, Kucukgergin C, Erdem S, et al (2012). Nitric oxide synthase (eNOS4a/b) gene polymorphism is associated with tumor recurrence and progression in superficial bladder cancer cases. J Urol, 188, 2398-403. https://doi.org/10.1016/j.juro.2012.07.096
  2. Are C, Rajaram S, Are M, et al (2013). A review of global cancer burden: trends, challenges, strategies, and a role for surgeons. J Surg Oncol, 107, 221-6. https://doi.org/10.1002/jso.23248
  3. Arikan S, Cacina C, Guler E, et al (2012). The effects of NOS3 Glu298Asp variant on colorectal cancer risk and progression in Turkish population. Mol Biol Rep, 39, 3245-9. https://doi.org/10.1007/s11033-011-1092-8
  4. Barbieri A, Palma G, Rosati A, et al (2012). Role of endothelial nitric oxide synthase (eNOS) in chronic stress-promoted tumour growth. J Cell Mol Med, 16, 920-6. https://doi.org/10.1111/j.1582-4934.2011.01375.x
  5. Brankovic A, Brajuskovic G, Nikolic Z, et al (2013). Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population. Int J Exp Pathol, 94, 355-61. https://doi.org/10.1111/iep.12045
  6. Burke AJ, Sullivan FJ, Giles FJ,Glynn SA (2013). The yin and yang of nitric oxide in cancer progression. Carcinogenesis, 34, 503-12. https://doi.org/10.1093/carcin/bgt034
  7. Chen SQ, Hong BB, Lin XD, et al (2010). Association of the eNOS G894T polymorphism with the development and progression of gastric cancer. J Chongqing Med Univ, 35, 1816-9.
  8. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al (1999). Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest, 103, 401-6. https://doi.org/10.1172/JCI5347
  9. Chen ZG, Zhou W, Chen W, Tao ZH,Gu YF (2009). Association of G894T polymorphism in endothelial nitric oxide synthase gene with prostate cancer. Chin J Healthy Lab Technol, 19, 289-91.
  10. Conde MC, Ramirez-Lorca R, Lopez-Jamar JM, et al (2006). Genetic analysis of caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep, 16, 353-9.
  11. Dong LM, Potter JD, White E, et al (2008). Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA, 299, 2423-36. https://doi.org/10.1001/jama.299.20.2423
  12. Erdamar S, Bagci P, Oz B, Dirican A (2006). Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON, 11, 213-6.
  13. Fu H, Zhang Y, Jin L, Ding Z (2011). Endothelial nitric oxide synthase (eNOS) G894T polymorphism is not associated with breast cancer risk: new evidence. Breast Cancer Res Treat, 128, 595-8. https://doi.org/10.1007/s10549-011-1438-x
  14. Fukumura D, Gohongi T, Kadambi A, et al (2001). Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A, 98, 2604-9. https://doi.org/10.1073/pnas.041359198
  15. Funke S, Hoffmeister M, Brenner H,Chang-Claude J (2009). Effect modification by smoking on the association between genetic polymorphisms in oxidative stress genes and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev, 18, 2336-8. https://doi.org/10.1158/1055-9965.EPI-09-0507
  16. Ghilardi G, Biondi ML, Cecchini F, et al (2003). Vascular invasion in human breast cancer is correlated to T786C polymorphism of NOS3 gene. Nitric Oxide, 9, 118-22. https://doi.org/10.1016/j.niox.2003.09.002
  17. Hao YJ, Montiel R,Huang YS (2010). Endothelial nitric oxide synthase (eNOS) 894 G > T polymorphism is associated with breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 124, 809-13. https://doi.org/10.1007/s10549-010-0833-z
  18. Harman E, Karadeniz M, Biray C, et al (2009). The relation of adiponectin and tumor necrosis factor alpha levels between endothelial nitric oxide synthase, angiotensin-converting enzyme, transforming growth factor beta, and tumor necrosis factor alpha gene polymorphism in adrenal incidentalomas. J Endocrinol Invest, 32, 881-8. https://doi.org/10.1007/BF03345766
  19. Hefler LA, Grimm C, Lantzsch T, et al (2006). Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat, 98, 151-5. https://doi.org/10.1007/s10549-005-9143-2
  20. Hefler LA, Ludwig E, Lampe D, et al (2002). Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol, 86, 134-7. https://doi.org/10.1006/gyno.2002.6749
  21. Jang MJ, Jeon YJ, Kim JW, et al (2013). Association of eNOS polymorphisms (-786T>C, 4a4b, 894G>T) with colorectal cancer susceptibility in the Korean population. Gene, 512, 275-81. https://doi.org/10.1016/j.gene.2012.10.032
  22. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  23. Lee KM, Choi JY, Lee JE, et al (2007). Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement. Breast Cancer Res Treat, 106, 433-8. https://doi.org/10.1007/s10549-007-9506-y
  24. Lee KM, Kang D, Park SK, et al (2009). Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis, 30, 621-5. https://doi.org/10.1093/carcin/bgp028
  25. Li Y, Ambrosone CB, McCullough MJ, et al (2009). Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk. Carcinogenesis, 30, 777-84. https://doi.org/10.1093/carcin/bgp053
  26. Lu J, Wei Q, Bondy ML, et al (2006). Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer, 107, 2245-53. https://doi.org/10.1002/cncr.22269
  27. Marangoni K, Araujo TG, Neves AF,Goulart LR (2008). The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression. BMC Cancer, 8, 273. https://doi.org/10.1186/1471-2407-8-273
  28. Marangoni K, Neves AF, Cardoso AM, et al (2006). The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prev, 30, 7-13. https://doi.org/10.1016/j.cdp.2005.09.004
  29. Marsden PA, Heng HH, Scherer SW, et al (1993). Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem, 268, 17478-88.
  30. Medeiros R, Morais A, Vasconcelos A, et al (2002). Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev, 11, 343-50. https://doi.org/10.1097/00008469-200208000-00005
  31. Nakayama M, Yasue H, Yoshimura M, et al (1999). T-786 -> C mutation in the 5 '-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation, 99, 2864-70. https://doi.org/10.1161/01.CIR.99.22.2864
  32. Ozturk E, Dikensoy E, Balat O, et al (2011). Association of endothelial nitric oxide synthase gene polymorphisms with endometrial carcinoma: a preliminary study. J Turk Ger Gynecol Assoc, 12, 229-33.
  33. Perera FP (1997). Environment and cancer: who are susceptible? Science, 278, 1068-73. https://doi.org/10.1126/science.278.5340.1068
  34. Reiche EM, Nunes SO,Morimoto HK (2004). Stress, depression, the immune system, and cancer. Lancet Oncol, 5, 617-25. https://doi.org/10.1016/S1470-2045(04)01597-9
  35. Riener EK, Hefler LA, Grimm C, et al (2004). Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. Gynecol Oncol, 93, 686-90. https://doi.org/10.1016/j.ygyno.2004.03.030
  36. Royo JL, Moreno-Nogueira JA, Galan JJ, et al (2006). Lack of association between NOS3 Glu298Asp and breast cancer risk: a case-control study. Breast Cancer Res Treat, 100, 331-3. https://doi.org/10.1007/s10549-006-9258-0
  37. Ryk C, Wiklund NP, Nyberg T,de Verdier PJ (2011). Polymorphisms in nitric-oxide synthase 3 may influence the risk of urinary-bladder cancer. Nitric Oxide, 25, 338-43. https://doi.org/10.1016/j.niox.2011.06.003
  38. Safarinejad MR, Safarinejad S, Shafiei N,Safarinejad S (2013). Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol Oncol, 31, 1132-40. https://doi.org/10.1016/j.urolonc.2012.01.002
  39. Sanli O, Kucukgergin C, Gokpinar M, et al (2011). Despite the lack of association between different genotypes and the presence of prostate cancer, endothelial nitric oxide synthase a/b (eNOS4a/b) polymorphism may be associated with advanced clinical stage and bone metastasis. Urol Oncol, 29, 183-8. https://doi.org/10.1016/j.urolonc.2009.04.011
  40. Tu YT, Tao J, Liu YQ, et al (2006). Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis. Clin Exp Dermatol, 31, 413-8. https://doi.org/10.1111/j.1365-2230.2006.02123.x
  41. Unal MT, Karabulut HG, Gumus-Akay G, et al (2010). Endothelial nitric oxide synthase gene polymorphism in gastric cancer. Turk J Gastroenterol, 21, 338-44. https://doi.org/10.4318/tjg.2010.0118
  42. Verim L, Toptas B, Ozkan NE, et al (2013). Possible relation between the NOS3 Gene GLU298ASP polymorphism and bladder cancer in Turkey. Asian Pac J Cancer Prev, 14, 665-8. https://doi.org/10.7314/APJCP.2013.14.2.665
  43. Wang XL, Mahaney MC, Sim AS, et al (1997). Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol, 17, 3147-53. https://doi.org/10.1161/01.ATV.17.11.3147
  44. Yao L, Fang F, Zhong Y,Yu L (2010). The association between two polymorphisms of eNOS and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 124, 223-7. https://doi.org/10.1007/s10549-010-0800-8
  45. Yeh CC, Santella RM, Hsieh LL, Sung FC,Tang RP (2009). An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. Int J Cancer, 124, 1565-71. https://doi.org/10.1002/ijc.24114
  46. Ying L,Hofseth LJ (2007). An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res, 67, 1407-10. https://doi.org/10.1158/0008-5472.CAN-06-2149
  47. Yu JX, Cui L, Zhang QY, et al (2006). Expression of NOS and HIF-1alpha in human colorectal carcinoma and implication in tumor angiogenesis. World J Gastroenterol, 12, 4660-4. https://doi.org/10.3748/wjg.v12.i29.4660
  48. Yuan F, Zhang LS, Li HY, et al (2013). Influence of angiotensin I-converting enzyme gene polymorphism on hepatocellular carcinoma risk in China. DNA Cell Biol, 32, 268-73. https://doi.org/10.1089/dna.2012.1910
  49. Ziaei SA, Samzadeh M, Jamaldini SH, et al (2013). Endothelial nitric oxide synthase Glu298Asp polymorphism as a risk factor for prostate cancer. Int J Biol Markers, 28, 43-8. https://doi.org/10.5301/JBM.2012.9585
  50. Zintzaras E, Grammatikou M, Kitsios GD, et al (2010). Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer: a genetic association study and meta-analysis. J Hum Genet, 55, 743-8. https://doi.org/10.1038/jhg.2010.100

Cited by

  1. T-786C, G894T, and Intron 4 VNTR (4a/b) Polymorphisms of the Endothelial Nitric Oxide Synthase Gene in Bladder Cancer Cases vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2199
  2. The T-786C, G894T, and intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene in prostate cancer cases vol.52, pp.2, 2016, https://doi.org/10.1134/S1022795416020022